ROCHE DIAGNOSTICS TINA-QUANT IGA GEN.2 03507343190

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional,u report with the FDA on 2015-08-20 for ROCHE DIAGNOSTICS TINA-QUANT IGA GEN.2 03507343190 manufactured by Roche Diagnostics.

Event Text Entries

[23863490] This event occurred in (b)(6).
Patient Sequence No: 1, Text Type: N, H10


[23863491] The customer reported that they received erroneous results for one patient sample tested for tina-quant immunoglobulin a gen. 2 (iga). The sample initially resulted as 36 mg/dl on a c501 analyzer and this result was reported outside of the laboratory to the physician. On (b)(6) 2015, the customer performed electrophoresis on the sample and found a peak for iga at 61%. Refer to the attachment for the specific electrophoresis data. For the electrophoresis results, it was stated that there was "presence of two monoclonal components, one is beta- globulin, which corresponds to 26% (3. 02 g/dl) and another one is gama- globulin, which corresponds to 2% (0. 23 g/dl) from total proteins. " the result from the c501 analyzer was not consistent with the electrophoresis result or patient condition. The laboratory called the doctor and informed the doctor of the electrophoresis results. It was then decided to dilute the sample in order to check for a result that was in accordance with the electrophoresis results. The sample was diluted 1:10 and the iga result was 24 mg/dl. The sample was diluted 1:20 and the iga result was 671 mg/dl. The sample was repeated again without dilution, resulting as 23 mg/dl for iga. The sample was also repeated again with a 1:20 dilution, resulting as 840 mg/dl for iga. According to the customer, only the results obtained with the 1:20 dilution were in accordance with the electrophoresis results. The patient was not adversely affected. The c501 analyzer serial number was (b)(4).
Patient Sequence No: 1, Text Type: D, B5


[28329746] A specific root cause could not be determined based on the provided information. A possible root cause may be related the characteristics of the patient sample. The information provided indicated the patient has myeloma. Gammopathy may be a consequence of myeloma. Product labeling states that gammopathy may cause interference with the iga assay. It was also reported that the instrument had a lot of issues related to preventive maintenance and these have since been corrected. The maintenance status of the instrument may also be a possible root cause.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number1823260-2015-04001
MDR Report Key5019019
Report SourceFOREIGN,HEALTH PROFESSIONAL,U
Date Received2015-08-20
Date of Report2015-10-06
Date of Event2015-07-07
Date Mfgr Received2015-07-23
Date Added to Maude2015-08-20
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactNA MICHAEL LESLIE
Manufacturer Street9115 HAGUE ROAD NA
Manufacturer CityINDIANAPOLIS IN 46250
Manufacturer CountryUS
Manufacturer Postal46250
Manufacturer Phone3175214343
Manufacturer G1ROCHE DIAGNOSTICS GMBH
Manufacturer StreetSANDHOFERSTRASSE 116 NA
Manufacturer CityMANNHEIM (BADEN-WURTTEMBERG) 68305
Manufacturer CountryGM
Manufacturer Postal Code68305
Single Use3
Previous Use Code3
Removal Correction NumberNA
Event Type3
Type of Report3

Device Details

Brand NameROCHE DIAGNOSTICS TINA-QUANT IGA GEN.2
Generic NameIGA, ANTIGEN, ANTISERUM, CONTROL
Product CodeCZP
Date Received2015-08-20
Model NumberNA
Catalog Number03507343190
Lot Number178354
ID NumberNA
OperatorHEALTH PROFESSIONAL
Device AvailabilityY
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerROCHE DIAGNOSTICS
Manufacturer Address9115 HAGUE ROAD NA INDIANAPOLIS IN 46250 US 46250


Patients

Patient NumberTreatmentOutcomeDate
10 2015-08-20

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.